AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Autolus Therapeutics Secures EC Approval for AUCATZYL in Leukemia Treatment, Stock Up 301.24%
ByAinvest
Wednesday, Jul 23, 2025 1:25 pm ET1min read
Autolus Therapeutics has secured European Commission approval for AUCATZYL to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The drug's approval is based on findings from the FELIX study. Analysts forecast an average target price of $9.67 with a potential upside of 301.24%. The company has a strong cash position of $516.6 million.
Autolus Therapeutics has received European Commission (EC) approval for its CAR T cell therapy, AUCATZYL (Obecabtagene Autoleucel), to treat adult patients (26 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The approval, based on data from the FELIX study, marks a significant milestone for the company.The FELIX study, an open-label, single-arm, phase 1b/2 trial, demonstrated that AUCATZYL was both efficacious and safe in this patient population. In cohort 2A, the overall remission rate among patients who received at least one infusion of AUCATZYL was 77%, with 55% achieving complete remission and 21% experiencing complete remission with incomplete hematologic recovery. The median duration of response was 14.1 months, and the median event-free survival (EFS) was 9.0 months [1].
The EC approval applies to all 27 European Union Member States, Iceland, Norway, and Liechtenstein. AUCATZYL is currently approved by the U.S. Food and Drug Administration (FDA) and authorized by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) [2].
Analysts have forecasted an average target price of $9.67 for Autolus Therapeutics, with a potential upside of 301.24%. The company's strong cash position of $516.6 million supports its market entry strategy in EU countries [3].
References:
[1] https://www.cancernetwork.com/view/european-commission-grants-marketing-authorization-to-obe-cel-in-r-r-b-all
[2] https://www.marketscreener.com/news/autolus-therapeutics-plc-car-t-therapy-aucatzyl-obecabtagene-autoleucel-granted-european-market-ce7c5cdcd888f427
[3] https://www.marketbeat.com/earnings/reports/2025-8-14-autolus-therapeutics-plc-stock/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet